The influence of selective (milrinone: 10, 50, 100 fiM) and nonselective phosphodiesterase (isobutyhnethylxanthine: 0.1, 10, 100 fiM) inhibitors and /J-adrenergic stimulation (isoproterenol: 0.01, 0.1 /xM) on phospholamban and myofibrillar protein phosphorylation was studied hi guinea pig hearts perfused with [ 32 P]orthophosphate. Changes hi protein phosphorylation were compared to alterations hi tissue cyclic AMP (cAMP) levels and positive inotropic effects induced by these agents. Isoproterenol (0.01 /*M), milrinone (50 fiM), and isobutyhnethylxanthine (100 fiM) all produced similar, twofold increases in dP/dt and -dP/dt but only stimulation with isobutylmethylxanthine and isoproterenol was associated with significant increases in phospholamban phosphorylation. At these equipotent doses, the effects of isobutyhnethylxanthine were associated with higher increases (3.1-fold) hi cAMP than those observed with isoproterenol (twofold). Milrinone (50 fiM) produced a 2.5-fold increase hi cAMP levels but failed to change phospholamban phosphorylation. Higher doses of milrinone (100 fiM) resulted hi relatively high (4.1-fold) cAMP levels, and this was associated with increased (1.5-fold) phosphorylation of phospholamban. Phosphorylation of troponin I was significantly increased at 0.01 fiM and 0.1 /iM isoproterenol, while phosphorylation of C protein was observed only at 0.1 ftM isoproterenol. Isobutyhnethylxanthine and milrinone did not significantly increase phosphorylation of either troponin I or C protein at any of the doses studied. These findings indicate that cardiotonic agents acting via the cAMP pathway may produce similar inotropic responses at different levels of cAMP and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. (Circulation Research 1989;64:104-111)
C hanges in the level of cyclic AMP (cAMP)
during the response of hearts to inotropic interventions may be due to alterations in the rates of separate processes regulating synthesis and breakdown of cyclic nucleotides. Activation of adenylate cyclase, for example, by /3-receptor stimulation, is one pathway which leads to the increased formation of cAMP. 1 An alternative pathway to elevate cellular cAMP is by the inhibition of phosphodiesterase^) (PDE) which catalyze its hydro-lysis. 2 Apart from the mechanisms for increases in cAMP, it is generally accepted that there is activation of cAMP-dependent protein kinases, which in turn may catalyze the phosphorylation of various intracellular proteins. 3 In cardiac cells, such phosphorylations may alter the function of proteins resulting in an increased Ca 2+ influx through the sarcolemmal Ca 2+ channels 4 as well as increased rate of Ca 2+ uptake and thus, storage of Ca 2+ in the sarcoplasmic reticulum. 5 Ultimately, there is an increase in contractility associated with a rise in Ca 2+ available to the myofibrillar proteins, which are also phosphorylated. 6 Previously, we have shown that /J-adrenergic stimulation of isolated beating hearts results in increased phosphorylation of phospholamban in sarcoplasmic reticulum (SR) and troponin I (Tnl) and C protein in the myofibrils. 7 - 9 Phosphorylation of phospholamban was associated with increases in SR Ca 2+ transport 9 and Ca
2+
-ATPase activity 10 in agreement with in vitro studies. 1112 Phosphorylation of myofibrillar proteins is also associated with a decreased Ca 2+ sensitivity of the myofibrillar Mg 2+ -ATPase activity. 9 These findings support the hypothesis that stimulation of SR Ca 2+ uptake and reduction of Ca 2+ sensitivity by the myofibrillar proteins, mediated by cAMP-dependent phosphorylation of phospholamban, Tnl, and C protein, may partially underly the myocardial effects of agents that increase cAMP.
The present study tests the hypothesis that increases in cAMP levels mediated by PDE inhibition are associated with in vivo protein phosphorylation similar to that observed with /3-adrenergic stimulation of the heart. The nonspecific PDE inhibitor isobutylmethylxanthine (IBMX), 1314 along with the specific PDE inhibitor milrinone, 1314 which has been recently shown to inhibit selectively the PDE type IV associated with canine cardiac SR, 15 were used. Our studies were designed to answer whether PDE inhibition by IBMX and milrinone is associated with 1) increases in tissue cAMP levels and positive inotropic and enhanced relaxation responses and 2) increases in phosphorylation of phospholamban, Tnl, and C protein.
Materials and Methods

Heart Perfusion
Hearts from anesthetized (30 mg/kg sodium pentobarbital) and heparinized (5,000 units/kg) Hartley guinea pigs (600-700 g) were rapidly excised and immediately cannulated for retrograde aortic perfusion of the coronary arteries with Krebs-Henseleit balanced salt solution. 1617 The Krebs-Henseleit solution contained (mM) 118 NaCl, 4.7 KC1, 2.5 CaCl 2 , 1.2 Mg 2 SO<, 25 NaHC0 3 , 0.5 Na 2 EDTA, 0.26 KHjPO*, and 5.5 glucose, yielding a total Ca 2+ concentration of 2.0 mM and a K + concentration of 4.9 mM. The buffer solution was saturated with 95% O 2 -5% CO 2 , which maintained a pH of 7.4; perfusion temperature was set at 37±0.2° C. The hearts were perfused at a constant aortic pressure of 65 mm Hg, initially for 20-30 minutes in a nonrecirculating flow to allow the preparations to stabilize. The perfusion circuit was switched to a recirculating flow containing 120 ml of the same buffer and to which 1-2 mCi of ["PJorthophosphate ("Pi in H 2 O; NEN Research Products, Boston, Massachusetts) was added for 30 minutes. After this labeling period, the circuit was returned to a nonrecirculating flow with nonradioactive buffer for 2 minutes, and drugs of interest were then introduced into the buffer flow line, at a point just before the perfusion fluid entered the coronary system. At the peak of the positive inotropic response to each cardiotonic agent (approximate perfusion times: 1 minute with isoproterenol, 4 minutes with IBMX and milrinone), the hearts were freeze-clamped with precooled (-196° C) Wollenberger clamps, powdered, and stored under liquid nitrogen. Left ventricular pressure and its first derivative, dP/dt, were measured through an indwelling apical catheter attached to a calibrated Statham transducer (Gould Instruments, Cleveland, Ohio) and were recorded simultaneously on a multichannel polygraph (Grass Instruments, Quincy, Massachusetts).
Drugs
We 
Membrane Vesicle Preparations
Microsomal preparations enriched in SR vesicles were prepared by minor modifications of procedures previously described. 8 The frozen powdered tissue was simultaneously thawed and homogenized in 20 ml Medium I for 15 seconds with a Polytron PT-10 (setting of 6; Brinkmann Instruments, Westbury, New York). Medium I consisted of 30 mM KH 2 PO< (pH 7.0), 10 mM NaF, 5 mM EDTA, 0.3 M sucrose with 0.3 mM phenylmethylsulphonyl fluoride, and 0.5 mM dithiothreitol added before homogenization. The homogenate was centrifuged at 4,300g for 10 minutes. The resulting supernatant fraction was filtered through four layers of cheesecloth, and the filtrate was centrifuged at 15,000g for 20 minutes. The supernatant fraction was again passed through four layers of cheesecloth and centrifuged at 143,000g for 30 minutes. The pellet was resuspended in Medium II (Medium I plus 0.5 M KC1) and centrifuged at 143,000g for 45 minutes. The resulting pellet was washed in Medium I for 30 minutes at 143,000g, and the final pellet was suspended in 0.5 ml of Medium I. The yield was 1-2 mg microsomal protein/heart. Protein was measured by the method of Lowry et al, 18 with bovine serum albumin as a standard. Enzyme marker assays revealed that microsomal mitochondrial content was approximately 35%, and sarcolemmal contamination was less than 10%; neither value changed with treatments.
Cardiac Myofibrillar Preparations
Functional myofibrils were purified by slight modification of procedures described previously. 19 -20 Briefly, the starting material for the preparation of myofibrils was the pellet obtained after the first centrifugation of heart homogenate (see above). These pellets were resuspended in 45 ml of inhibiting buffer (100 mM KH 2 PO 4 ,50 mM NaF, and 5 mM EDTA, pH 7.0), homogenized, and centrifuged at 3,500# for 10 minutes. This washing procedure was repeated once. Resulting pellets were then resus-pended in inhibiting buffer containing 1% Triton X-100 and were centrifuged at 3,5OOg for 10 minutes. The pellets were subsequently washed three times as above with standard buffer (60 mM KC1, 30 mM Imidazole, and 2 mM MgCl 2 , pH 7.0) containing 10 mM NaF. The resulting pellet was resuspended in a final volume (5 ml) of standard buffer containing 10 mM NaF. The yield was 30-40 mg of myofibrillar protein/heart as determined according to the Lowry method. 18 
Gel Electrophoresis
Polyacrylamide gel electrophoresis under denaturing conditions was performed by the procedures described by Laemmli 21 with a 5-18% gradient acrylamide slab gel. Samples of ^P -labeled SR or 32 P-labeled myofibrils were solubilized by addition of an equal volume of sample buffer containing 62.5 mM Tris-HCl (pH 6.8), 6% sodium dodecyl sulfate, 20% glycerol, 5% /3-mercaptoethanol, and a trace of bromophenol blue as a tracking dye. Generally, 150-200 fj u g of sample protein were applied to each lane and electrophoresis was conducted at 35 mA/ gel. In each set of experiments, two identically loaded gels were run with one gel being placed into fixative (20% trichloroacetic acid; 5% methanol; 1% glycerol) for 24 hours after electrophoresis. The second gel was dried, and autoradiography was performed by placing the dried gel in contact with Kodak OG-1 film in Kodak Lanex Regular cassettes (with intensifying screens; Rochester, New York) at -70° C for 24-72 hours. The radioactive bands corresponding to phospholamban, Tnl, and C protein were identified on the appropriate autoradiograms and then cut from the fixed gel for counting in nonaqueous scintillation fluid. Phosphate incorporation into the various proteins was quantified by dividing the Pincorporation in each band by the specific activity of [y-P]ATP determined for that heart, and expressed as picomoles Pj per milligram protein.
Cyclic AMP Assay
Tissue cAMP content in samples from 
Other Assays
The specific activity of [y- 32 P]ATP in each heart was determined from the specific radioactivity of [ 32 P]-phosphocreatine extracted and assayed as described by Kopp and Barany. 22 Generally, 200 ^ig samples of powdered tissue were used for this determination. There was no significant change in the specific activity of [-y- Statistical analysis was performed using the Student's t test for unpaired observations.
Results
Phospholamban Phosphorylation by Phosphodiesterase Inhibitors and ^-Adrenergic Stimulation
The /3-adrenergic agonist isoproterenol and the PDE inhibitors milrinone and IBMX were examined for their ability to increase In agreement with previous observations, isoproterenol increased 32 P-incorporation into proteins with apparent Af r =27,000 and 11,000 (left panels of Figures 1 and 2, arrows) , the high and low molecular weight forms of phospholamban. 910 The electrophoretic mobility of the 27,000 M r form of phospholamban could be altered by varying the solubilization conditions prior to electrophoresis. Boiling of the SR samples in 6% sodium dodecyl sulfate for 5 minutes completely converted the high M r form of phospholamban into the 11,000 M r form (Figure 1 , left panel, lanes 5 and 6; Figure 2 , left panel, lanes 3 and 4), as has previously been reported. 910 Treatment with isoproterenol at 0.1 fiM resulted in a 4.6-fold increase in 32 P-incorporation into phospholamban over control, while treatment with 0.01 fiM isoproterenol resulted in a 2.2-fold increase (left panels of Figures 1 and 2 ; Table 1 ). A third major protein, with an apparent M T of 15,000, also displayed an isoproterenol-induced increase in 32 Pincorporation. This phosphoprotein, whose mobility did not change upon boiling, is probably of sarcolemmal membrane origin. 23 Exposure to the nonspecific PDE inhibitor IBMX at concentrations of 0.1 pM did not appear to alter -incorporation into phospholamban while concentrations of 10 ^AM were associated with slight increases (Figure 1, left panel, lanes 3 and 4; Table 1 ). Elevating the IBMX concentration to 100 fiM produced a significant increase (1.6-fold) in phospholamban phosphorylation (Figure 2 , left panel, lanes 5 and 6; Table  1 ). Lindemann and Watanabe 24 have previously reported that IBMX induced larger increases in contractility and "P-incorporation into phospholamban in perfused guinea pig hearts compared to those observed in this study. The reason for this discrepancy may be related to differences in experimental conditions including perfusion temperature and cardiac frequency, thereby reflecting differences in the potential for changes in contractility. 25 ' 26 When perfused hearts were exposed to the selective PDE type IV inhibitor, milrinone, at concentrations of 10 fiM and 50 /JM, no effects on phos- 
FIGURE 1. Autoradiography of sodium dodecyl sulfate (0.1%) polyacrylamide (5-18%) gel electrophoresis of sarcoplasmic reticulum (150 fig) and myofibrils (100 fig) isolated from guinea pig hearts perfused with [ n P]orthophosphate. Sarcoplasmic reticulum enriched membrane preparations (left) and myofibrils (right) were isolated from hearts frozen after perfusion with Krebs-Henseleit buffer (CON), 10 fiM isobutylmethylxanthine (IBMX) for 4 minutes, 0.1 fiM isoproterenol (ISO) for 1 minute, or 50 fiM milrinone (MIL) for 4 minutes. Some samples were held at room temperature (-boil) while others were boiled for 5 minutes (+boil) before electrophoresis, as described in "Materials and Methods." PLB H , high molecular weight form of phospholamban; PLB L , low molecular weight form of phospholamban.
-PLBĤ• Table 1 ).
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Myofibrillar Protein Phosphorylation by Phosphodiesterase Inhibitors and f3-Adrenergic Stimulation
Myofibrils were prepared from the same hearts used in the studies for SR phosphorylation, described above. Isoproterenol stimulation was associated with an increase in the extent of phosphorylation of Tnl and a 130,000-140,000 M r protein (Figure 1 , right panel, lanes 5 and 6; Figure 2 , right panel, lanes 3 and 4), most likely C protein.
927 Concentrations of 0.01 fiM produced a 2.0-fold increase in Tnl phosphorylation, while 0.1 fiM isoproterenol produced a 2.5-fold increase (Table 1) . However, changes in C protein phosphorylation were demonstrated only with 0.1 fiM isoproterenol (1.6-fold increase). Perfusion of guinea pig hearts with either IBMX or milrinone in doses up to 100 /JM did not alter Tnl or C protein phosphorylation levels. In agreement with data showing a failure of the PDE inhibitors to increase Tnl and C protein phosphorylation, there was a lack of effect on Ca 2+ activation of myofibrillar Mg 2+ -dependent ATPase activity (data not shown).
Effects of Phosphodiesterase Inhibitors and (3-Adrenergic Stimulation on cAMP Levels and Contraction/Relaxation
Data summarized in Table 1 show that in the presence of 10 /iM and 100 fjM IBMX, cAMP levels were elevated respectively by 1.5 and 3.7 times compared with control. In response to milrinone there was a 2.5-fold increase in cAMP levels at 50 /xM and a 4.1-fold increase at 100 /AM. Perfusions of hearts with isoproterenol were associated with a 1.8-fold increase in cAMP levels at 0.01 /nM and a 5.4-fold increase at 0.1 /xM. Levels of myocardial activity, as measured by +dP/dt (contraction) and -dP/dt (relaxation), were determined in the same hearts from which SR vesicles and myofibrillar preparations were isolated. Isoproterenol at 0.01 fiM produced an approximate 2.0-fold stimulation in +dP/dt and -dP/dt, and these responses were similar to responses obtained with 100 /xM IBMX and 50 fiM milrinone (Table 1 ). This level of activation by 0.01 /xM isoproterenol correlated well with its ability to elevate cAMP levels and phosphorylation of phospholamban and Tnl. IBMX at 100 AIM elevated "P-incorporation into phospholamban to levels similar to those obtained with 0.01 /xM isoproterenol. However, this increase in phospholamban phosphorylation by IBMX was associated with levels of cAMP two times higher than those observed with 0.01 /iM isoproterenol ( Figure 3) . Milrinone (50 elevated cAMP to levels similar to those demonstrated with 0.01 /iM isoproterenol, but there was no change in protein phosphorylation observed. Perfusions of hearts with 100 piM milrinone resulted in further elevation in cAMP levels (twofold higher than those observed with 0.01 /xM isoproterenol) but produced only a modest increase in 32 Pincorporation into phospholamban. With this concentration, there was a decreased positive inotropic response (1.5-fold of control) as compared with 50 /AM milrinone (2.1-2.3-fold increase). Compared with 0.01 /xM isoproterenol, higher doses of isoproterenol (0.1 (xM) were associated with increases in +dP/dt and -dP/dt and cAMP levels, but only phosphorylation of phospholamban increased significantly (Table 1) .
Discussion
Our results demonstrate that the PDE inhibitor agents IBMX and milrinone can significantly elevate intracellular cAMP and cardiac contractility and relaxation with little or no stimulation of SR and myofibrillar protein phosphorylation in intact hearts. In contrast, an equipotent concentration of isoproterenol produced similar increases in cAMP levels and in phosphorylation of phospholamban and Tnl.
One possible explanation for the demonstrated lack of effect on SR and myofibrillar protein phosphorylation by the PDE inhibitors is that these agents may have an alternative cellular site of action. It is known that /3-agonists increase Ca 2+ influx via the slow inward channels, 28 and evidence indicates that in vivo /3-adrenergjc stimulation is associated with increased phosphorylation of a sarcolemmal 15,000 M r protein. 23 Isobutylmethylxanthine 29 and milrinone 30 have been shown to increase transsarcolemmal Ca 2+ influx, and this may play a role in their positive inotropic effects. It is plausible then that the biochemical mechanisms involved in the positive inotropic effects of these two drugs are through cAMP-dependent phosphorylation of sarcolemmal protein(s), which may increase transsarcolemmal Ca 2+ influx. Intracellular Ca 2+ so elevated would be available for enhanced myofilament activation and SR Ca 2+ uptake and release and may ultimately lead to increased tension development.
A more complex interpretation of our data relates to the possible cellular compartmentation of phosphodiesterase isozymes, cAMP, protein kinases, and their substrates. Functional compartmentation of cAMP and protein kinases has previously been proposed for cardiac muscle. 31 -33 In relation to this concept, there is evidence that PDEs are also compartmentalized in heart. 33 Milrinone is known to specifically inhibit the "low K m " or "cGMPinhibited" PDE type IV isozyme, 1314 which recently has been demonstrated to be membrane-bound and associated with the SR in dog heart. 15 Inhibition of this PDE isozyme could lead to localized increases in cAMP and cAMP-dependent protein kinase pools and thus to increases in phospholamban phosphorylation. However, recent evidence by Weishaar et al 34 indicates that most of this PDE isozyme is found in the soluble compartment of guinea pig heart cells rather than in the membrane-bound form. These findings are consistent with our observations that low concentrations of milrinone (^50 pM), despite elevating cAMP and contraction/relaxation activities, failed to elicit changes in phospholamban phosphorylation. The increase in tension the peak of the intracellular Ca 2+ transient and with increases in the rates of Ca 2+ release and uptake by the SR. 33 At higher concentrations of milrinone (100 /nM) we observed low levels of phospholamban phosphorylation, which may be due either to inhibition of the small amounts of SR membrane-bound PDE type IV isozyme or to higher activation of the cAMP-dependent protein kinase(s). Alternatively, phospholamban phosphorylation may be due to Ca 2+ /calmodulin-dependent protein kinase, activated by the increased trans-sarcolemmal Ca 2+ influx. This is, however, less likely to occur in view of evidence 36 demonstrating a lack of effect on phospholamban phosphorylation by changes in extracellular Ca 2+ . We observed that the increase in contractility was less at 100 IJM milrinone than at 50 piM milrinone, although cAMP levels were 1.5-fold larger at the higher drug concentration. The reasons for this effect are likely to be complex but may be due to direct inhibition of cAMP-dependent protein kinase activity by milrinone.
Apparently, milrinone and IBMX were not able to activate a cAMP-dependent compartment(s) associated with the myofibrils, since no changes in Tnl or C protein phosphorylation were observed. This was supported by a lack of effect on the Ca 2+ -dependence of the Mg 2+ -ATPase activity of myofibrils isolated from hearts perfused with milrinone and IBMX (data not shown). Moreover, there is no evidence for a direct effect of milrinone on myofibrillar ATPase activity.*»
In conclusion, our findings with guinea pig hearts indicate that PDE inhibitors can enhance contraction and relaxation with little or no change in phosphorylation of SR and contractile proteins, despite relatively large increases in tissue cAMP levels. The lack of increase in protein phosphorylation may be due to complex effects on protein kinases and phosphatases regulating SR and myofibrillar function, while the increase in contractility may be due to effects at the level of the sarcolemma.
